{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T10:32:46Z","timestamp":1655893966690},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.encep.2007.06.004","type":"journal-article","created":{"date-parts":[[2008,4,23]],"date-time":"2008-04-23T12:27:03Z","timestamp":1208953623000},"page":"170-178","source":"Crossref","is-referenced-by-count":11,"title":["Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone"],"prefix":"10.1016","volume":"34","author":[{"given":"P.-M.","family":"Llorca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bouhours","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Moreau-Mallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.encep.2007.06.004_bib1","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"American Diabetes Association","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.encep.2007.06.004_bib2","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.encep.2007.06.004_bib3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2007.06.004_bib4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/070674370404900504","article-title":"New antipsychotics, compliance, quality of life and subjective tolerability \u2013 are patients better off?","volume":"49","author":"Awad","year":"2004","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.encep.2007.06.004_bib5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2165\/00002018-199410060-00005","article-title":"Long-term depot antipsychotics: a risk-benefit assessment","volume":"10","author":"Barnes","year":"1994","journal-title":"Drug Saf"},{"key":"10.1016\/j.encep.2007.06.004_bib6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0924-9338(99)00173-X","article-title":"Subjective quality of life in schizophrenic patients living in the community. Relationship to clinical and social characteristics","volume":"1999","author":"Bengtsson-Tops","year":"1999","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.encep.2007.06.004_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0924-977X(03)00109-3","article-title":"A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia","volume":"14","author":"Bhanji","year":"2004","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.encep.2007.06.004_bib8","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.2337\/diabetes.53.7.1782","article-title":"Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the bruneck study","volume":"53","author":"Bonora","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.encep.2007.06.004_bib9","first-page":"4","article-title":"Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia","volume":"65","author":"Casey","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2007.06.004_bib10","first-page":"233","article-title":"Extrapyramidal symptom rating scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.encep.2007.06.004_bib11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1586\/14737175.3.4.435","article-title":"Risperidone long-acting injection","volume":"3","author":"Chue","year":"2003","journal-title":"Expert Rev Neurotherapeutics"},{"key":"10.1016\/j.encep.2007.06.004_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0924-2708.2004.00067.x","article-title":"The impact of weight gain associated with atypical antipsychotic use in schizophrenia","volume":"16","author":"Chue","year":"2004","journal-title":"Acta Neuropsychiatr"},{"key":"10.1016\/j.encep.2007.06.004_bib13","doi-asserted-by":"crossref","first-page":"16-L22","DOI":"10.1056\/NEJMoa002028","article-title":"A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia","volume":"346","author":"Csernansky","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.encep.2007.06.004_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2165\/00023210-200216070-00004","article-title":"Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics","volume":"16","author":"Csernansky","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.encep.2007.06.004_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1176\/appi.ajp.159.1.103","article-title":"Antipsychotic medication adherence: is there a difference between typical and atypical agents?","volume":"159","author":"Dolder","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2007.06.004_bib16","doi-asserted-by":"crossref","unstructured":"Eerdekens M, Fleischhacker WW, Xie Y et al. (2002). Long-term safety of long-acting risperidone microspheres. The American Psychiatric Nurses Association annual meeting, 5\u20138 October, Dallas, Texas. American Psychiatric Nurses Association.","DOI":"10.1016\/S0924-9338(02)80826-4"},{"key":"10.1016\/j.encep.2007.06.004_bib17","first-page":"18","article-title":"Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics","volume":"64","author":"Ereshefsky","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2007.06.004_bib18","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.4088\/JCP.v64n1017","article-title":"Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second generation antipsychotic","volume":"64","author":"Fleischhacker","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2007.06.004_bib19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1176\/appi.ajp.161.4.692","article-title":"Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia","volume":"161","author":"Gilmer","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2007.06.004_bib20","first-page":"218","article-title":"Clinical global impressions","volume":"76","author":"Guy","year":"1976"},{"key":"10.1016\/j.encep.2007.06.004_bib21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/00023210-200418020-00005","article-title":"Long-acting risperidone. A review of its use in schizophrenia","volume":"18","author":"Harrison","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.encep.2007.06.004_bib22","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00004850-200101001-00002","article-title":"Progress defined \u2013 short-term efficacy, long-term effectiveness","volume":"16","author":"Kane","year":"2001","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.encep.2007.06.004_bib23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0924-977X(97)00045-X","article-title":"Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy","volume":"8","author":"Kane","year":"1998","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.encep.2007.06.004_bib24","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","article-title":"Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic","volume":"160","author":"Kane","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2007.06.004_bib25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.encep.2007.06.004_bib26","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.4088\/JCP.v64n1105","article-title":"Partial compliance and patient consequences in schizophrenia: our patients can do better","volume":"64","author":"Keith","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2007.06.004_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2165\/00023210-200418002-00002","article-title":"Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life","volume":"18","author":"Lambert","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.encep.2007.06.004_bib28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.eurpsy.2003.11.007","article-title":"Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone","volume":"19","author":"Lasser","year":"2004","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.encep.2007.06.004_bib29","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1176\/appi.ajp.160.7.1209","article-title":"Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials","volume":"160","author":"Leucht","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2007.06.004_bib30","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.4088\/JCP.v65n0809","article-title":"Safety and efficacy of long-acting risperidone in schizophrenia: a 12-Week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics","volume":"65","author":"Lindenmayer","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2007.06.004_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00044011-200424050-00004","article-title":"Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder. Symptoms, quality of life and resource use under customary clinical care","volume":"2004","author":"Mahmoud","year":"2004","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.encep.2007.06.004_bib32","first-page":"3","article-title":"Overview of partial compliance","volume":"64","author":"Marder","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2007.06.004_bib33","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2007.06.004_bib34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","article-title":"The MOS 36-item short-form health survey (SF-36\u00ae): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs","volume":"31","author":"McHorney","year":"1993","journal-title":"Med Care"},{"key":"10.1016\/j.encep.2007.06.004_bib35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004850-200505000-00001","article-title":"Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies","volume":"20","author":"Moeller","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.encep.2007.06.004_bib36","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4088\/JCP.v65n0412","article-title":"Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone","volume":"65","author":"Nasrallah","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2007.06.004_bib37","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1600-0447.1997.tb10133.x","article-title":"A survey of the attitudes of chronic psychiatric patients living in the community toward their medication","volume":"95","author":"Pereira","year":"1997","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.encep.2007.06.004_bib38","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/00005650-199907000-00008","article-title":"Reliability, validity and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol","volume":"37","author":"Tunis","year":"1999","journal-title":"Med Care"},{"key":"10.1016\/j.encep.2007.06.004_bib39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.yic.0000133500.92025.20","article-title":"Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics","volume":"19","author":"Turner","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.encep.2007.06.004_bib40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/01.yic.0000122861.35081.16","article-title":"Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone","volume":"19","author":"van Os","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.encep.2007.06.004_bib41","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36\u00ae): I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700607000590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700607000590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T17:10:16Z","timestamp":1557508216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013700607000590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S0013700607000590"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2007.06.004","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}